Literature DB >> 30482773

Super-Enhancer-Associated Long Noncoding RNA HCCL5 Is Activated by ZEB1 and Promotes the Malignancy of Hepatocellular Carcinoma.

Li Peng1,2,3, Binyuan Jiang1,4, Xiaoqing Yuan2,5, Yuntan Qiu2,3, Jiangyun Peng2,3, Yongsheng Huang2,3, Chaoyang Zhang1, Yin Zhang2,3, Zhaoyu Lin2,6, Jinsong Li2,6, Weicheng Yao2,3, Weixi Deng2,3, Yaqin Zhang1, Meng Meng2,3, Xi Pan7, Chunquan Li8, Dong Yin2,3, Xinyu Bi9, Guancheng Li10,11, De-Chen Lin12,3.   

Abstract

Hepatocellular carcinoma (HCC) is one of the most dominant causes of neoplasm-related deaths worldwide. In this study, we identify and characterize HCCL5, a novel cytoplasmic long noncoding RNA (lncRNA), as a crucial oncogene in HCC. HCCL5 promoted cell growth, G1-S transition, invasion, and metastasis while inhibiting apoptosis of HCC cells both in vitro and in vivo. Moreover, HCCL5 was upregulated in TGF-β1-induced classical epithelial-to-mesenchymal transition (EMT) models, and this lncRNA in turn accelerated the EMT phenotype by upregulating the expression of transcription factors Snail, Slug, ZEB1, and Twist1. HCCL5 was transcriptionally driven by ZEB1 via a super-enhancer and was significantly and frequently overexpressed in human HCC tissues, correlating with worse overall survival of patients with HCC. Together, this study characterizes HCCL5 as a super-enhancer-driven lncRNA promoting HCC cell viability, migration, and EMT. Our data also suggest that HCCL5 may serve as a novel prognostic biomarker and therapeutic target in HCC. SIGNIFICANCE: These findings identify the lncRNA HCCL5 as a super-enhancer-driven oncogenic factor that promotes the malignancy of hepatocellular carcinoma. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30482773     DOI: 10.1158/0008-5472.CAN-18-0367

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

1.  LncRNA OIP5-AS1 promotes cell proliferation and migration and induces angiogenesis via regulating miR-3163/VEGFA in hepatocellular carcinoma.

Authors:  Changsheng Shi; Qing Yang; Songsong Pan; Xingcheng Lin; Gending Xu; Ya Luo; Bingru Zheng; Xiangpang Xie; Mingxu Yu
Journal:  Cancer Biol Ther       Date:  2020-04-24       Impact factor: 4.742

2.  Elevated LINC01550 induces the apoptosis and cell cycle arrest of melanoma.

Authors:  Jia Chen; Ping Li; Zizi Chen; Shaohua Wang; Shijie Tang; Xiang Chen; Zhizhao Chen; Jianda Zhou
Journal:  Med Oncol       Date:  2021-02-20       Impact factor: 3.064

3.  LncSEA: a platform for long non-coding RNA related sets and enrichment analysis.

Authors:  Jiaxin Chen; Jian Zhang; Yu Gao; Yanyu Li; Chenchen Feng; Chao Song; Ziyu Ning; Xinyuan Zhou; Jianmei Zhao; Minghong Feng; Yuexin Zhang; Ling Wei; Qi Pan; Yong Jiang; Fengcui Qian; Junwei Han; Yongsan Yang; Qiuyu Wang; Chunquan Li
Journal:  Nucleic Acids Res       Date:  2021-01-08       Impact factor: 16.971

4.  Super enhancer-LncRNA SENCR promoted cisplatin resistance and growth of NSCLC through upregulating FLI1.

Authors:  Qiang Shen; Huixin Zhou; Meijuan Zhang; Ruihao Wu; Liangxing Wang; Yumin Wang; Jie Chen
Journal:  J Clin Lab Anal       Date:  2022-05-02       Impact factor: 3.124

5.  LncRNA FOXP4-AS1 is activated by PAX5 and promotes the growth of prostate cancer by sequestering miR-3184-5p to upregulate FOXP4.

Authors:  Xingcheng Wu; Yu Xiao; Yi Zhou; Zhien Zhou; Weigang Yan
Journal:  Cell Death Dis       Date:  2019-06-17       Impact factor: 8.469

6.  Super-Enhancer-Associated LncRNA UCA1 Interacts Directly with AMOT to Activate YAP Target Genes in Epithelial Ovarian Cancer.

Authors:  Xianzhi Lin; Tassja J Spindler; Marcos Abraão de Souza Fonseca; Rosario I Corona; Ji-Heui Seo; Felipe Segato Dezem; Lewyn Li; Janet M Lee; Henry W Long; Thomas A Sellers; Beth Y Karlan; Houtan Noushmehr; Matthew L Freedman; Simon A Gayther; Kate Lawrenson
Journal:  iScience       Date:  2019-06-20

7.  LncRNA MAFG-AS1 promotes the malignant phenotype of ovarian cancer by upregulating NFKB1-dependent IGF1.

Authors:  Yang Bai; Chenchen Ren; Baojin Wang; Jingge Xue; Feiyan Li; Jiaxi Liu; Li Yang
Journal:  Cancer Gene Ther       Date:  2021-05-25       Impact factor: 5.987

Review 8.  The Landscape of lncRNAs in Hepatocellular Carcinoma: A Translational Perspective.

Authors:  Juan Pablo Unfried; Paloma Sangro; Laura Prats-Mari; Bruno Sangro; Puri Fortes
Journal:  Cancers (Basel)       Date:  2021-05-28       Impact factor: 6.639

9.  MiR-4269 suppresses the tumorigenesis and development of pancreatic cancer by targeting ZEB1/OTX1 pathway.

Authors:  Xin Sui; Zhenghui Sui
Journal:  Biosci Rep       Date:  2020-06-26       Impact factor: 3.840

10.  Super-enhancer-driven AJUBA is activated by TCF4 and involved in epithelial-mesenchymal transition in the progression of Hepatocellular Carcinoma.

Authors:  Chi Zhang; Shi Wei; Wei-Peng Sun; Kai Teng; Miao-Miao Dai; Feng-Wei Wang; Jie-Wei Chen; Han Ling; Xiao-Dan Ma; Zi-Hao Feng; Jin-Ling Duan; Mu-Yan Cai; Dan Xie
Journal:  Theranostics       Date:  2020-07-11       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.